-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Raises Price Target to $10

Benzinga·05/12/2026 16:55:10
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and raises the price target from $7 to $10.